Drug
RVL-1201
RVL-1201 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
3
75%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 33 (75.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
NCT01848041
completedphase_3
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
NCT02436759
completedphase_3
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
NCT03536949
completedphase_3
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
NCT03565887
Clinical Trials (4)
Showing 4 of 4 trials
NCT01848041Phase 1
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
NCT02436759Phase 3
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
NCT03536949Phase 3
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
NCT03565887Phase 3
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4